Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted Cytoplasm Note=Secreted by macrophages and circulates in the blood (PubMed:24223991, PubMed:24804991). Transported in the cytoplasm via CD36-mediated endocytosis (By similarity). |
Domain |
PF00530 Scavenger receptor cysteine-rich domain |
Function |
Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflammed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis, associates with cytosolic FASN, inhibiting fatty acid synthase activity and leading to lipolysis, the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC, the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells, where it decreases the content of polyunsaturated fatty acyls (PUFA), affecting two metabolic proteins MSMO1 and CYP51A1, which synthesize ligands of RORC, limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity-associated autoimmunity via its association with IgM, interfering with the binding of IgM to Fcalpha/mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed:24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed:16030018, PubMed:24223991, PubMed:24583716, PubMed:25713983). |
Biological Process |
GO:0006898 receptor-mediated endocytosis GO:0006968 cellular defense response |
Molecular Function |
GO:0005044 scavenger receptor activity GO:0038024 cargo receptor activity |
Cellular Component |
GO:0072562 blood microparticle |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CD5L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CD5L and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CD5L in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CD5L in various data sets.
|
Points in the above scatter plot represent the mutation difference of CD5L in various data sets.
|
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD5L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD5L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD5L. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD5L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CD5L expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CD5L and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CD5L |
Name | CD5 molecule-like |
Aliases | Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CD5L collected from DrugBank database. |
There is no record. |